The complex haemolytic toxicity problem of primaquine in G6PD deficient patients puts that drug out of the reach of approximately 14% of people living at risk of infection by P. vivax (assuming an equal risk of infection across the population, see Footnotes 1, 2). This evidence concerns the gene G6PD and infection.